If you have been using compounded semaglutide or tirzepatide, the FDA's regulatory actions in 2025 and 2026 mean you may need to transition to a brand-name medication sooner than you planned. The good news: this transition can be smooth if you plan ahead. The bad news: gaps in treatment lead to weight regain, and regain happens fast — studies show approximately two-thirds of lost weight returns within a year of stopping.
This guide covers the practical steps to switch without interruption.
Step 1: Know Your Current Dose
Compounded semaglutide is typically prescribed in milligrams per week, the same unit used for brand-name Wegovy. However, compounded dosing is sometimes less standardized — some patients are on custom doses between the standard titration steps, or on doses measured from vials where precision varies.
Before you switch, confirm your exact current weekly dose with your prescriber. This is the starting point for mapping to a brand-name equivalent.
Semaglutide Dose Mapping
| Compounded Dose (weekly) | Nearest Wegovy Injectable Dose | Oral Wegovy Option |
|---|---|---|
| 0.25 mg | Wegovy 0.25 mg | 1.5 mg daily (starting dose) |
| 0.5 mg | Wegovy 0.5 mg | 4 mg daily |
| 1.0 mg | Wegovy 1.0 mg | 9 mg daily |
| 1.7 mg | Wegovy 1.7 mg | 25 mg daily |
| 2.4 mg | Wegovy 2.4 mg (maintenance) | 25 mg daily |
If you are on compounded tirzepatide, the mapping to Zepbound is more direct since tirzepatide doses are the same between compounded and brand-name: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg weekly.
Step 2: Secure Your Brand-Name Access Before Stopping Compounded
The most common mistake patients make is running out of their compounded supply before the brand-name prescription is filled and ready. Insurance prior authorizations can take days to weeks. Pharmacy stock may be limited. Telehealth consultations need to be scheduled.
Start the transition process while you still have compounded medication remaining. Ideally, have your brand-name prescription filled and in hand before your last compounded dose.
Step 3: Choose Your Access Pathway
Insurance: Contact your insurer's pharmacy benefits department and ask specifically about coverage for Wegovy or Zepbound for weight management. If covered, ask about prior authorization requirements and typical approval timelines. Have your prescriber submit the prior auth as early as possible.
Manufacturer savings programs: Novo Nordisk offers self-pay pricing for Wegovy tablets starting at $149/month. Eli Lilly's LillyDirect offers Zepbound at approximately $399/month. These do not require insurance.
Medicare GLP-1 Bridge: If you are a Medicare Part D beneficiary, the $50/month Bridge program launches July 1, 2026. Coordinate with your prescriber to submit the prior authorization when the program opens.
New telehealth provider: If your current telehealth provider only offered compounded products, you may need to find a provider that prescribes brand-name medications. Many platforms have already transitioned their formularies.
Step 4: Time the Switch
For injectable semaglutide: take your last compounded dose on your regular injection day. Begin your brand-name Wegovy injection on your next scheduled injection day (one week later). There should be no gap — the medications contain the same active ingredient at the same dosing frequency.
For switching to oral semaglutide: your prescriber will determine the appropriate oral starting dose based on your current injectable dose. The transition may involve a brief overlap or a carefully timed switch. Follow your prescriber's guidance on timing.
For tirzepatide: same principle — take your last compounded dose, then start brand-name Zepbound on your next weekly injection day at the equivalent dose.
Do not restart titration unless your prescriber advises it. If you have been on a stable compounded dose for months, you should generally transition to the equivalent brand-name dose directly — not restart from the lowest titration step. Restarting titration unnecessarily delays reaching therapeutic levels and reduces the medication's effectiveness during the transition period. Discuss this explicitly with your prescriber.
Step 5: Monitor the Transition
Even though the active ingredient is the same, some patients report subtle differences when switching between compounded and brand-name formulations. This may be due to differences in formulation, concentration, or inactive ingredients. Side effects may temporarily increase or decrease.
Keep a brief log during the first 2–4 weeks after switching: appetite changes, GI symptoms, energy level, and weight. Share this with your prescriber at your next follow-up. Any significant changes should prompt a conversation about dose adjustment.
What If You Cannot Afford the Brand-Name?
If the cost difference between compounded and brand-name medication is a barrier, explore every available discount before discontinuing treatment entirely. The landscape has changed — options exist now that did not a year ago.
Oral Wegovy at $149/month for the starting dose is approaching the price point of many compounded semaglutide products. Manufacturer copay assistance programs can reduce insured costs to $25/month or less. Patient assistance programs exist for uninsured patients. And the Medicare Bridge program provides $50/month access for eligible beneficiaries starting July 2026.
Discontinuing treatment entirely should be a last resort, discussed with your healthcare provider, with a clear plan for managing potential weight regain.
Find Brand-Name GLP-1 Providers
Compare telehealth providers offering brand-name Wegovy and Zepbound prescriptions with transparent self-pay pricing.
Compare Providers